|1.||Schwedhelm, Edzard: 7 articles (01/2015 - 02/2010)|
|2.||Böger, Rainer H: 6 articles (01/2015 - 02/2010)|
|3.||Segarra, Gloria: 4 articles (01/2009 - 12/2002)|
|4.||Martens-Lobenhoffer, Jens: 3 articles (01/2015 - 01/2011)|
|5.||Bode-Böger, Stefanie M: 3 articles (01/2015 - 01/2012)|
|6.||Szuba, Andrzej: 3 articles (02/2014 - 12/2008)|
|7.||Lüneburg, Nicole: 3 articles (01/2014 - 02/2012)|
|8.||Kielstein, Jan T: 3 articles (01/2014 - 01/2012)|
|9.||Teerlink, Tom: 3 articles (10/2013 - 10/2004)|
|10.||Maas, Renke: 3 articles (03/2013 - 02/2010)|
|1.||Kidney Diseases (Kidney Disease)
07/01/2015 - "Symmetric Dimethylarginine Assay Validation, Stability, and Evaluation as a Marker for the Early Detection of Chronic Kidney Disease in Dogs."
01/01/2015 - "Circulating symmetric dimethylarginine (SDMA) is increased in patients with chronic kidney disease. "
10/01/2011 - "Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease."
05/01/2011 - "Levels of ADMA and its isomer symmetric dimethylarginine (SDMA), which does not inhibit nitric oxide synthesis, are both elevated in patients with kidney disease. "
11/01/2014 - "Comparison of serum concentrations of symmetric dimethylarginine and creatinine as kidney function biomarkers in cats with chronic kidney disease."
|2.||Liver Diseases (Liver Disease)
01/01/2009 - "Previous studies have shown that asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and nitric oxide (NO) play a prominent role in liver dysfunction. "
09/01/2015 - "Previous studies on arginine metabolites reported an association of asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) with liver dysfunction and an inverse relation of homoarginine (hArg) with cardiovascular risk. "
|3.||Cardiovascular Diseases (Cardiovascular Disease)
07/01/2009 - "While increased plasma levels of ADMA have been reported in different cardiovascular disease states, its association with symmetric dimethylarginine (SDMA) has not been evaluated in a prospective population-based study. "
03/01/2013 - "Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study."
02/01/2012 - "The methylated arginines (MAs) monomethylarginine (MMA), asymmetric dimethylarginine (ADMA), and symmetric dimethylarginine (SDMA) have been shown to be independent predictors of cardiovascular disease. "
01/01/2014 - "To investigate determinants of asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA), including single nucleotide polymorphisms (SNPs), in the DDAH1, DDAH2, and AGXT2 genes and their associations with prevalent and incident cardiovascular disease (CVD) in older adults with type 2 diabetes mellitus. "
03/01/2011 - "Serum ADMA, arginine and symmetric dimethylarginine (SDMA) levels were assessed by liquid chromatography in 61 AS and 26 osteoarthritis (OA) patients with no known cardiovascular disease. "
|4.||Chronic Kidney Failure (Chronic Renal Failure)
03/01/1999 - "In this study, the plasma concentrations of ADMA, symmetric dimethylarginine, and L-arginine were determined in relation to plasma nitrate levels (as an index of NO formation) for a group of 80 patients with ESRD. "
09/01/2009 - "Asymmetric dimethylarginine (ADMA)and symmetric dimethylarginine (SDMA) originate from hydrolysis of methylated proteins, including dietary proteins, and are retained in end-stage renal disease(ESRD). "
08/01/2009 - "To investigate the roles of insulin, glucose, and oxidative stress on plasma asymmetric and symmetric dimethylarginine (ADMA, SDMA) levels in complicated diabetes, we studied patients with type 1 diabetes (T1D; n = 20), T1D + end-stage renal disease under hemodialysis (T1D + ESRD; n = 12), T1D + ESRD who received kidney transplant (KD; n = 16), and T1D + ESRD who received kidney-pancreas transplant (KP; n = 20) and healthy controls (n = 50). "
12/01/2006 - "We confirmed that compared with age- and gender-matched healthy controls, ESRD patients have excessive oxidative stress and arginine methylation as indexed by elevated plasma levels of oxidation products of lipids (13-hydroxyoctadecadienoic acid (13-HODE)), thiols (oxidized:reduced glutathione, oxidized glutathione (GSSG):GSH), proteins, and nucleic acids, and the methylation products ADMA and symmetric dimethylarginine (SDMA). "
02/01/2011 - "The relationship between asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) plasma concentrations and acute heart failure is unknown. "
12/01/2012 - "L-Arginine, ADMA, and symmetric dimethylarginine (SDMA) were measured by liquid chromatography-tandem mass spectrometry in 341 patients with chronic heart failure due to dilated cardiomyopathy (DCM; n = 226) or ischemic cardiomyopathy (ICM; n = 115). "
11/01/2011 - "The aim of this study was to investigate the effect of pharmacological treatment on symmetric dimethylarginine (SDMA), ADMA and arginine plasma concentrations in patients with acute congestive heart failure (ACHF) through the evaluation of type-1 system cationic amino acid transporter-1/type 1 dimethylarginine dimethylaminohydrolases-1 (CAT-1/DDAH-1). "
04/01/2015 - "Nitric oxide dysregulation in patients with heart failure: the association of depressive symptoms with L-arginine, asymmetric dimethylarginine, symmetric dimethylarginine, and isoprostane."
|2.||N,N-dimethylarginine (asymmetric dimethylarginine)
|3.||Brain Natriuretic Peptide (Natrecor)
|4.||pro-brain natriuretic peptide (1-76)
|5.||Nitric Oxide (Nitrogen Monoxide)
|7.||Endothelin-1 (Endothelin 1)
|8.||Uric Acid (Urate)
|4.||Renal Dialysis (Hemodialysis)